Disclosure Of Entity's Operating Segments [Text Block]

Hyloris Pharmaceuticals SA - Filing #3166306

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
Disclosure of entity's operating segments [text block]
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue
3,096 EUR
175,000 EUR
Share of profit (loss) of associates and joint ventures accounted for using equity method
191,000 EUR
Tax expense (income)
297,000 EUR
1,000 EUR
Profit (loss) before tax
11,282 EUR
7,145 EUR
Profit (loss)
11,579 EUR
7,145 EUR
Assets
63,444 EUR
69,182 EUR
Liabilities
15,388 EUR
10,123 EUR
Cash flows from (used in) operating activities
11,250 EUR
4,570 EUR
Cash flows from (used in) investing activities
3,075 EUR
633,000 EUR
Cash flows from (used in) financing activities
62,000 EUR
69,397 EUR
Disclosure of products and services [text block]
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]
Disclosure of major customers [abstract]
Disclosure of major customers [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.